Displaying 41 - 60 of 137
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published Sort ascending
MHRA-100275-PIP01-21
  • SEMAGLUTIDE
  • Treatment of non-alcoholic steatohepatitis (NASH)
  • Ozempic
  • OZEMPIC 0.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
  • Ozempic
  • Ozempic
  • Ozempic
  • Ozempic
  • OZEMPIC 0.25 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
  • OZEMPIC 1 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
  • Gastroenterology-Hepatology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100208-PIP01-21
  • Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain
  • Treatment of non-alcoholic steatohepatitis
  • Gastroenterology-Hepatology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100230-PIP01-21
  • Thienopyrimidine Derivative
  • Treatment of fibrosing interstitial lung disease
  • Pneumology - Allergology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100254-PIP01-21
  • epcoritamab
  • Treatment of mature B-cell malignancies
  • Not available at present
  • Oncology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100291-PIP01-21
  • imetelstat
  • Treatment of acute myeloid leukaemia
  • Treatment of Myelodysplastic Syndromes (MDS), including JMML
  • Oncology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100179-PIP01-21
  • vemircopan
  • Treatment of paroxysmal nocturnal haemoglobinuria
  • Haematology-Hemostaseology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100179-PIP01-21
  • vemircopan
  • Treatment of paroxysmal nocturnal haemoglobinuria
  • Haematology-Hemostaseology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100196-PIP01-21
  • SARS-CoV-2 virus, beta-propiolactone inactivated
  • Prevention of coronavirus disease 2019 (COVID-19)
  • Not available
  • Vaccines
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100232-PIP01-21
  • ALECTINIB
  • Treatment of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
  • Alecensa
  • Alecensa
  • Oncology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100140-PIP01-21
  • BENRALIZUMAB
  • Treatment of Hypereosinophilic syndrome (HES)
  • FASENRA
  • FASENRA
  • FASENRA
  • FASENRA
  • FASENRA PEN
  • FASENRA
  • Haematology-Hemostaseology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100106-PIP01-21
  • 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxaminde
  • sodium chloride solution 4.2% (w/v)
  • Treatment of primary ciliary dyskinesia
  • Pneumology - Allergology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100150-PIP01-21
  • AZITHROMYCIN
  • Prevention of bronchopulmonary dysplasia (BPD)
  • Pneumology - Allergology
  • Neonatology - Paediatric Intensive Care
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100050-PIP01-21
  • efgartigimod alfa
  • Treatment of Immune thrombocytopenia
  • Haematology-Hemostaseology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100196-PIP01-21
  • SARS-CoV-2 virus, beta-propiolactone inactivated
  • Prevention of coronavirus disease 2019 (COVID-19)
  • Not available
  • Vaccines
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 17/05/2022
MHRA-100053-PIP01-21-M01 (update)
  • IMDEVIMAB
  • Treatment of coronavirus disease 2019 (COVID-19)
  • Prevention of Coronavirus Disease 2019 (COVID-19)
  • Ronapreve
  • Ronapreve
  • Ronapreve
  • Ronapreve
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 04/05/2022
MHRA-100052-PIP01-21-M01 (update)
  • CASIRIVIMAB
  • Treatment of coronavirus disease 2019 (COVID-19)
  • Prevention of coronavirus disease 2019 (COVID-19)
  • Ronapreve
  • Ronapreve
  • Ronapreve
  • Ronapreve
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 04/05/2022
MHRA-100276-PIP01-21-M01 (update)
  • BRODALUMAB
  • Treatment of psoriasis
  • brodalumab
  • Lumicef
  • Siliq
  • Kyntheum
  • Dermatology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 04/05/2022
MHRA-100279-PIP01-21
  • Humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide
  • Diabetic retinopathy
  • Ophthamology
W: decision granting a waiver in all age groups for the listed condition(s). No 04/05/2022
MHRA-100339-PIP01-21
  • Autologous selected renal cells
  • Treatment of Chronic Kidney Disease
  • Not available at present
  • Uro-Nephrology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No 04/05/2022
MHRA-100390-PIP01-21-M01 (update)
  • Highly purified single-stranded, 5'-capped mRNA encoding full length SARS-CoV2 spike protein (BNT162b2)
  • Prevention of coronavirus disease 2019 (COVID-19)
  • Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)
  • Comirnaty 30 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)
  • Vaccines
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/04/2022